GE Healthcare Expands European Capabilities
News Apr 12, 2016
GE Healthcare’s Life Sciences’ European manufacturing and distribution site for sterile liquids has expanded its capabilities to include production of large volumes of buffers, process liquids and cell culture media, and launched a rapid production service for prototype cell culture media and buffers. The site in Pasching, Austria, mirrors the high quality and performance standards of the business’ Center of Excellence in Logan, Utah, meeting customers’ requirements for consistent global quality management.
Biopharmaceuticals and vaccines are used in the treatment of cancer, autoimmune disorders and other areas of unmet medical need. Manufacturing of these biopharmaceuticals requires a reliable, flexible supply of a range of sterile liquids, including cell culture media and buffers, to support high-yield production and efficient purification of the target product. The Pasching facility serves biopharmaceutical companies in over 40 countries across Europe, Africa and the Middle East.
Development and scale-up of bioprocesses frequently require quick manufacture of prototype media and buffers to facilitate timely process evaluation and fast implementation. GE’s Pasching site now also offers Rapid Response Production services, enabling production of small volumes of prototype cell culture media and buffers within five days of ordering. The use of consistent and replicable manufacturing practices supports efficient future transfer to cGMP production for biomanufacturers.
David Radspinner, PhD, General Manager of Bioprocess Cell Culture at GE Healthcare’s Life Sciences business, said: “Our aim is to accelerate development and scale-up for our biomanufacturing customers by providing simplified, flexible services both in Europe and in other regions. The capabilities of our Pasching facility will enable us to seamlessly support our customers globally, ensuring security of supply with multiple manufacturing sites that are qualified and validated to the same quality standards.”
GE’s additional production capacity at Pasching has been developed over two years, with an investment of $4.3m USD (€3.8m). The site is also a production and distribution centre for Europe, with more than 300,000 individual product items shipped through the site per year.
UT Southwestern researchers have succeeded in neutralizing what they believe is a primary factor in late-onset Alzheimer’s disease, opening the door to development of a drug that could be administered before age 40, and taken for life, to potentially prevent the disease in 50 to 80 percent of at-risk adults.READ MORE
Tight junctions are multi-protein complexes that serve as barriers in epithelial tissues such as the skin or lining of the gut. Loss of a specific tight junction barrier protein, claudin 18, occurs in the majority of gastric cancer patients and is correlated with poor prognosis in patients with advanced gastric cancer.READ MORE